Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297947 · ClinicalTrials.gov registry record · Phase 2
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
A Phase 2 study of Schizophrenia and Schizoaffective Disorder, sponsored by Manhattan Psychiatric Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00297947: Completed Phase 2 study of Schizophrenia and Schizoaffective Disorder, sponsored by Manhattan Psychiatric Center.
NCT00297947 is a Phase 2 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Manhattan Psychiatric Center. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00297947, a Phase 2 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Manhattan Psychiatric Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.
Conditions Studied
Interventions
- DRUG quetiapine
Study Locations (2)
New York
- Manhattan Psychiatric Center - New York
- Nathan Kline Institute for Psychiatric Research - Orangeburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT00297947 record still lists
NCT00297947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which quetiapine is the first listed.
NCT00297947 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00297947 about?
NCT00297947 is a clinical study titled "High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder". This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.
What is the current status of trial NCT00297947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-12. Estimated completion is 2014-10.
What conditions does trial NCT00297947 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT00297947?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00297947?
This trial is sponsored by Manhattan Psychiatric Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00297947 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00297947's enrollment target sits among peer trials
60 188th of 315 higher than 119 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia